Hello misui143, I have enjoyed reading your intelligent

New Post Public Reply Private Reply Replies (1) Message Board
blafarm misiu143 #20056
547
Hello misui143,

I have enjoyed reading your intelligent and informed posts since arriving here.

Quote:
It is very nice that you are a new poster , you are here since February 7, 2020


Yes, that is true. I recently joined after spending too much time reading caustic and baseless posts on Seeking Alpha. However, that was not my first post. If you are so inclined you can inspect my other posts using this link: https://investorshangout.com/profile/latestposts/id/62885. Feel free to also inspect my very few posts on "CYDY IH Eyes Only" board.

Quote:
But look to me that you all the way surprised !!!!!.
You surprise with any good information given by the company....not important what Dr NP or Dr Patterson said .......


Not exactly sure what you mean or what you are implying. I am thrilled with reports of what this little molecule can do. The potential indications seem to keep growing, and I find myself thinking about all of the people who can maybe be helped or saved by this drug.

I find Dr. Patterson to be extremely informed, articulate and credible. Frankly, I wish that he was the Chief Medical Officer or Chief Scientific Officer of the company, and that he participated in ALL conference calls, and ALL videos. Dr. NP has clearly accomplished what few others in the industry could ever do, through sheer will and perseverance.

Quote:
" To this day , I am particularly confused as to why BP has no interest in the company "......( how you know that ?? ))


I don't know that, this is simply what it looks like from my outside perspective. I see no investments by, no co-development with, and no licensing deals with BP. I only see a deal with V that, lets face it, is not exactly the entity one would select as a business partner, if one had other options.

Not surprisingly, this leads to confusion. Why would such an important drug not be capturing the attention of BP? More specifically, what pharmaceutical company would not want to participate, on any level, with CYDY's impressive pipeline of indications? Maybe you know more details regarding historical interest expressed by BP -- if so, please share your knowledge.

Quote:
"Discounting COVID-19 as it is completely unproven " ....( really ??, well this is not what Dr Paterson is saying )


I must admit being surprised by this remark. If I am not mistaken, I believe you might be a doctor and/or a person of science. Forgive me if I am mistaken, however, when exactly did you decide that a hypothesis was a "proven" fact -- just because someone else said it was?

In my world, hypotheses are not considered proven facts -- until they are empirically tested and confirmed to be facts. I would be absolutely thrilled if leronlimab had efficacy in treating those unfortunate souls stricken by COVID-19. There are people dying all over the world. Can you imagine if leronlimab saved those lives?

However, until such time that leronlimab is actually tested and proven to save the lives of those stricken by COVID-19 -- it remains theoretical. Yes, one can say (as Dr. Paterson has) that the MOA has a good chance of being efficacious -- but that's why every pharmaceutical company in the world conducts clinical trials. Otherwise, everyone would be taking drugs simply because someone else said it would work. Frankly, I don't know a doctor or scientist who would disagree with this logic.

Quote:
"Whatever it is , there is something wrong with this picture " ( how do you know that ?? ))


I believe that I have generally expressed this notion above. However, I guess my issue is that I don't quite understand how a molecule that has all appearances of being, literally, one of the most important drugs in the history of mankind, is not widely known, and not being aggressively courted by BP.

Let's do a quick review of potential indications:

Esophagus, Squamous Head & Neck, Melanoma, Brain-Glioblastoma, Throat, Lung including Non-Small Cell, Stomach, Colon Carcinoma, Breast, Testicular, Ovarian, Uterine, Pancreas, Bladder, Thyroid, other Endocrine, Blood/Bone Marrow CLL, AML, Hodgkin’s and non-Hodgkin’s lymphoma, other liquid/Blood Tumors, Sarcomas, Crohn’s Disease, IBS (Inflammatory Bowel Syndrome), MS (Multiple Sclerosis) , Hashimoto’s Thyroiditis, Vasculitis, Psoriasis, Polymyositis, Autoimmune Hepatitis, Graves’ Disease, Sjogren’s Syndrome, Myasthenia gravis

Have I left anything out?

So, I'm sure you can imagine how a relatively new investor, who sees this extraordinary and mind-boggling list of potential indications, and doesn't see any tangible evidence of BP interest -- might say: "there is something wrong with this picture".

Quote:
And then you say... " I am long " ...really ... why ..??


Simply put -- I want to believe. I want to believe that a single drug can miraculously address this amazing plurality of diseases. I want to believe that millions of people suffering from these diseases can maybe have the opportunity to live long, healthy, and productive lives. I want to believe that the families and friends of those inflicted will have their loved ones in their lives for many years to come. And, in the interest of full disclosure, I sure wouldn't mind a financial benefit from my support of the company relating to my investment.

I believe I have adequately addressed your questions. It does make me sad to recognize that your curious line of inquiry has the trappings of someone who thinks that I am here specifically to spread negative information for financial gain. Allow me to disabuse you of that notion. I do not short this stock. I am long and strong, that is, until such time that the investment thesis is disproved. There's nothing more I can write that will dissuade you from that incorrect characterization.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Exploring the Growth of Automotive Catalysts Market Trends

Updated Category News Views 109

Growth of the Automotive Catalysts Market The automotive industry is experiencing notable growth in its need for innovative emission control technologies. This surge is primarily fueled by the increasing implementation of stringent environmental regulations and the collective aim for cleaner transportation solutions. The automotive catalysts market, valued at around US$...

Continue Reading
Innovative Move by Aurora Mobile to Enhance AI Capabilities

Updated Category News Views 172

Innovative Steps in AI Integration by Aurora Mobile SHENZHEN, China -- Aurora Mobile Limited (NASDAQ: JG), a prominent player in customer engagement and marketing technology, is making waves within the tech industry. The Company has announced an exciting initiative to integrate three advanced language models from Alibaba's renowned Qwen series. This strategic move...

Continue Reading
Sweetgreen's Nathaniel Ru Executes Major Share Transactions

Updated Category News Views 84

Nathaniel Ru's Major Transaction at Sweetgreen Sweetgreen, Inc. (NYSE: SG) has recently disclosed a significant transaction involving their Chief Brand Officer, Nathaniel Ru. According to the latest filings, he sold 38,295 shares of Class A Common Stock, totaling over $1.3 million. Details of the Sale This sale was executed at a weighted average price of $35.08 per share,...

Continue Reading
Andrew Blockinger Honored as Top Golf Professional of the Year

Updated Category News Views 247

Celebrating Excellence in Golf Professionalism KemperSports has recognized Andrew Blockinger, the head golf professional at Holly Hills, with the Emil Esposito Golf Professional of the Year Award. This announcement came during the annual KemperSports Leadership Conference, where golf professionals gather to celebrate achievements in the golf community. A Testament to...

Continue Reading
XPeng Achieves Record Revenue Growth and Future Ambitions

Updated Category News Views 142

XPeng's Impressive Financial Performance Chinese electric vehicle manufacturer XPeng Inc (NYSE: XPEV) has recently made headlines, revealing its substantial revenue growth and ambitious plans for the future. The company announced that it achieved an impressive quarterly revenue of 20.38 billion Chinese yuan, which is approximately $2.86 billion. This figure represents a...

Continue Reading